Abeona therapeutics announces completion of patient follow-up in pivotal phase 3 viital™ study of eb-101 in patients with recessive dystrophic epidermolysis bullosa (rdeb)

Topline viital™ study results expected within the next month topline viital™ study results expected within the next month

ABEO Ratings Summary

ABEO Quant Ranking